You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 9,605,064

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,605,064

Title:	Methods and compositions for treatment of skin disorders
Abstract:	The invention provides methods and compositions for the treatment of a skin disorder associated with detrimental TNF.alpha. activity, such as psoriasis. The invention includes methods for treating a skin disorder associated with detrimental TNF.alpha. activity, such as psoriasis, in a subject who has failed or lost response to prior biologic therapy, such as prior administration of etanercept. The invention further provides methods for determining the efficacy of a human TNF.alpha. antibody, or antigen-binding portion thereof, for the treatment of a skin disorder associated with detrimental TNF.alpha. activity, such as psoriasis.
Inventor(s):	Okun; Martin M. (Libertyville, IL), Hoffman; Rebecca S. (Wilmette, IL), Barker; Jonathan (London, GB)
Assignee:	AbbVie Biotechnology Ltd (Hamilton, BM)
Application Number:	12/859,181
Patent Claims:	1. A method for treating psoriasis in a subject who has failed to respond to or has lost responsiveness to etanercept and infliximab, the method comprising administering 80 mg of adalimumab subcutaneously to the subject, and administering 40 mg of adalimumab subcutaneously to the subject every other week starting one week following administration of the 80 mg of adalimumab to the subject. 2. The method of claim 1, wherein the subject failed to achieve a PASI 50 response after receiving etanercept and infliximab. 3. The method of claim 1, wherein the subject has a Psoriasis Area and Severity Index (PAST) of .gtoreq.10 and/or a Dermatology Life Quality Index (DLQI)>10. 4. The method of claim 1, wherein said 40 mg of adalimumab is comprised in a pre-filled syringe for subcutaneous injection. 5. The method of claim 1, wherein said 40 mg of adalimumab is formulated at a concentration of 50 mg/ml. 6. A method for treating psoriasis in a subject who has failed to respond to or has lost responsiveness to etanercept and infliximab, the method comprising administering 80 mg of adalimumab subcutaneously to the subject, and administering 40 mg of adalimumab subcutaneously to the subject weekly starting one week following administration of the 80 mg of adalimumab to the subject. 7. The method of claim 6, wherein the subject failed to achieve a PASI 50 response after receiving etanercept and infliximab. 8. The method of claim 6, wherein the subject has a Psoriasis Area and Severity Index (PASI) of .gtoreq.10 and/or a Dermatology Life Quality Index (DLQI)>10. 9. The method of claim 6, wherein said 40 mg of adalimumab is comprised in a pre-filled syringe for subcutaneous injection. 10. The method of claim 6, wherein said 40 mg of adalimumab is formulated at a concentration of 50 mg/ml. 11. The method of claim 1, wherein the subject has lost response to infliximab. 12. The method of claim 6, wherein the subject has lost response to infliximab.

Details for Patent 9,605,064

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2026-04-10
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2026-04-10
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2026-04-10
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2026-04-10
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007	⤷ Try a Trial	2026-04-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.